NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Meirluc,

You certainly may be right, but I would frankly be surprised if more than one or two of the current survivors are control patients, and unless a patient had a complete remission before the opportunity to cross over, I cannot see anyone doing it. My thought are all, or nearly all who didn't cross over may have passed on before the opportunity would have been available to them.

We have no idea what the terms of the SAP may be, or if they're even finalized. While I personally think it's crazy to wait for a specific number of deaths when people are living much longer than anticipated, the regulators are sometimes so set in their ways that it's not worth the battle you'd have to fight to make the change. It's also possible they're looking at the living patient in the trial the shortest period exceed XX number of months, over 48 sounds excessive to me, but anything is possible.

The last patient to enter the trial would be approaching 54 months I believe, I would hate to think they agreed to 60 months. In short, there is really no reason that a trial should be stretched out to this length, I believe the vaccines benefits would have been clear a couple years ago. Perhaps had more people died sooner the trial would have ended sooner, and would have been a success, especially in a disease that kills so many as quickly as GBM does.

Gary